01:53:33 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2025-02-27 Bokslutskommuniké 2024
2024-08-16 Halvårsrapport
2024-03-28 Årsstämma
2024-02-27 Bokslutskommuniké 2023
2023-08-18 Halvårsrapport
2023-05-05 X-dag ordinarie utdelning NXTMS 0.00 SEK
2023-03-31 Årsstämma
2023-02-27 Bokslutskommuniké 2022
2022-08-12 Halvårsrapport
2022-05-09 X-dag ordinarie utdelning NXTMS 0.00 SEK
2022-03-31 Årsstämma
2022-02-28 Bokslutskommuniké 2021
2021-08-13 Halvårsrapport
2021-05-17 Split NXTMS 100:1
2021-04-30 X-dag ordinarie utdelning NXTMS 0.00 SEK
2021-04-29 Årsstämma
2021-03-01 Extra Bolagsstämma 2021
2021-02-26 Bokslutskommuniké 2020
2020-08-14 Halvårsrapport
2020-04-01 X-dag ordinarie utdelning NXTMS 0.00 SEK
2020-02-28 Bokslutskommuniké 2019
2019-11-11 Extra Bolagsstämma 2019
2019-08-16 Halvårsrapport
2019-03-26 X-dag ordinarie utdelning NXTMS 0.00 SEK
2019-03-25 Årsstämma
2019-03-04 Bokslutskommuniké 2018
2018-11-26 Split NXTMS 30:1
2018-11-21 Extra Bolagsstämma 2018
2018-08-16 Halvårsrapport
2018-03-29 X-dag ordinarie utdelning NXTMS 0.00 SEK
2018-03-28 Årsstämma
2018-02-28 Bokslutskommuniké 2017
2017-08-16 Halvårsrapport
2017-03-29 X-dag ordinarie utdelning NXTMS 0.00 SEK
2017-03-28 Årsstämma
2017-02-28 Bokslutskommuniké 2016
2017-02-17 Extra Bolagsstämma 2017
2016-08-17 Halvårsrapport
2016-04-01 X-dag ordinarie utdelning NXTMS 0.00 SEK
2016-03-31 Årsstämma
2016-02-29 Bokslutskommuniké 2015
2015-12-22 Extra Bolagsstämma 2015
2015-08-20 Halvårsrapport
2015-04-01 X-dag ordinarie utdelning NXTMS 0.00 SEK
2015-03-31 Årsstämma
2015-02-26 Bokslutskommuniké 2014

Beskrivning

LandFinland
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Nexstim är verksamt inom medicinteknik. Bolaget har utvecklat en icke-invasiv teknik för hjärnstimulering som kallas SmartFocus®. Det är en navigerad magnetisk stimuleringsteknik (nTMS) med 3D-navigering som ger inriktning av TMS till det specifika området av hjärnan. Tekniken är avsedd för behandling av svår depression och kronisk neuropatisk smärta. Bolaget grundades år 2000 och har sitt huvudkontor i Helsingfors.
2020-08-27 13:30:00

Press release, Helsinki, 27 August 2020 at 14.30 (EEST)

Nexstim NBT® System with SmartFocus® TMS sold to Neurological Institute of Los Angeles

Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces that Neurological Institute of Los Angeles has purchased a Nexstim NBT® System with SmartFocus® TMS.

The Neurological Institute of Los Angeles (NILA) is a comprehensive, private neurological center that is focused on providing personalized patient care and on advancing neuroscience through novel research and clinical trials. They use Nexstim SmartFocus® TMS technology for depression therapy and research.

This is the fifth Nexstim NBT® system installed for depression treatment in California.

Mikko Karvinen, CEO of Nexstim, said: “We are happy to announce that The Neurological Institute of Los Angeles has decided to purchase the NBT® system after an evaluation period. SmartFocus® TMS continues to be subject of intensive research also outside its clinically validated indications which highlights its possible potential to treat a host of currently intractable brain diseases and disorders.”

Further information is available on the website www.nexstim.com, or by contacting:

Mikko Karvinen, CEO
+358 50 326 4101
mikko.karvinen@nexstim.com

About Nexstim Plc

Nexstim is a Finnish, globally operating medical technology company. Our mission is to enable personalized and effective therapies and diagnostics for challenging brain diseases and disorders.

Nexstim has developed a world-leading non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.

SmartFocus® technology is used in Nexstim’s proprietary Navigated Brain Therapy (NBT®) system, which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBT® system is CE marked for the treatment of major depression and chronic neuropathic pain.

In addition, Nexstim is commercializing its SmartFocus® based Navigated Brain Stimulation (NBS) system for diagnostic applications. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain. Nexstim shares are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.

For more information please visit www.nexstim.com